The Quantellect read.As of Nov 19, 2026, 11 active firms cover TransMedics Group Inc: 7 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $77.00 to $175.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $113.27 sits 17% above the current $96.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.46 next quarter toward $2.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy764%
Neutral436%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$113.27
+17.4% upside
Average target across 11 active firms as of Nov 19, 2026 vs $96.50 current
Highest Target$175.00
Average Target$113.27
Lowest Target$77.00
Detailed analyst forecasts for TMDX
Showing 1–12 of 12 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 7 of 11 active firms rate TMDX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TMDX EPS & revenue forecast
EPS · NEXT QUARTER
$0.46
Range $0.35 – $0.53 · 4 analysts · +55% YoY
Next period, 4 analysts expect TransMedics Group Inc to earn $0.46 a share (range $0.35 – $0.53), versus $0.30 a year earlier. Full-year consensus is $1.67, growing to $2.49 the year after.
REVENUE · NEXT QUARTER
$212.3M
Range $206.2M – $221.9M · 4 analysts · +22% YoY
Revenue is expected to reach $212.3M (range $206.2M – $221.9M), +22.1% year-over-year. Full-year consensus is $767.1M, rising to $901.4M next year.
Top analysts covering TransMedics Group Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TMDX.
#1
Mike Matson
Needham · Rank #285
Buy
$106.00+9.8% to target
Overall win rate
36%
+ Follow
#2
William Plovanic
Canaccord Genuity · Rank #370
Buy
$120.00+24.4% to target
Overall win rate
38%
+ Follow
#3
Matt O'Brien
Piper Sandler · Rank #561
Buy
$100.00+3.6% to target
Overall win rate
25%
+ Follow
#4
RD
Ryan Daniels
William Blair
Buy
No targeton TMDX
Coverage
—
+ Follow
#5
MO
Matthew O'Brien
Piper Sandler
Buy
$100.00+3.6% to target
Coverage
—
+ Follow
TMDX stock forecast FAQ
What is TMDX's average 12-month price target?+
The 11 active firms with a live target average $113.27 for TransMedics Group Inc over the next 12 months, ranging from a $175.00 high to a $77.00 low, as of Nov 19, 2026.
Is TMDX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TMDX?+
The Street-high target is $175.00 (Oppenheimer), and the Street-low is $77.00 (UBS). The average of all 11 active-firm targets is $113.27.
How many active Wall Street firms cover TMDX?+
11 active firms have a recognized rating on TransMedics Group Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TMDX?+
Among analysts who currently cover TMDX, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #285). Their current call is Buy with a $106.00 target.
What is TransMedics Group Inc's projected EPS for next quarter?+
The consensus estimate is $0.46 per share (range $0.35 – $0.53) across 4 analysts. Full-year EPS is projected at $1.67, rising to $2.49 the following year.
How much revenue is TransMedics Group Inc expected to report next quarter?+
Consensus revenue is $212.3M (range $206.2M – $221.9M). Full-year revenue is projected at $767.1M, growing to $901.4M next year.
Have analysts been upgrading or downgrading TMDX lately?+
As of Nov 19, 2026, 7 of 11 active firms rate TMDX a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TMDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.